Fundraising Fox
🦊/Companies
Sign in

Immuron

NASDAQ: IMRN

1 known investors

Find your way into Immuron

Immuron is an Australian biopharmaceutical company developing and commercialising targeted polyclonal antibodies aimed at addressing unmet medical needs. Its products, based on a patented technology platform, are formulated to reduce diarrhoea, support gastrointestinal and digestive health, and promote immune defence.

BiotechDigital HealthWellness & Fitness

Investors · 1

Silver Lake PartnersMenlo Park

In the news

IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTradestockstotrade.com · Sep 2026Immuron's cash rose A$6.2M to A$9M; its C. diff drug is ready for Phase 2stocktitan.net · Aug 2026Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 | Press Releases | mycarrollcountynews.commycarrollcountynews.com · Apr 2026Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Press Connects | Press & Sun-Bulletinpressconnects.com · Mar 2026Immuron secures DoD funding for new oral therapeutics against pathogens By Investing.comng.investing.com · Dec 2025Buy Immuron Stock – IMRN Stock Quote Today & Investment Insights - Public.compublic.com

Frequently asked questions

What does Immuron do?
Immuron is an Australian biopharmaceutical company developing and commercialising targeted polyclonal antibodies aimed at addressing unmet medical needs. Its products, based on a patented technology platform, are formulated to reduce diarrhoea, support gastrointestinal and digestive health, and promote immune defence.
Who are Immuron's investors?
Immuron's investors include Silver Lake Partners.